WillItSurvive
Pharma and healthcare groups · Spain

Grifols

grifols.com ↗

Spanish maker of plasma-derived medicines like immunoglobulins and albumin.

Defensible for now
Assessed 31 July 2026 · Evidence as of 31 July 2026
Real protection, with named pressure against it.
On the recordSince 31 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Decision on U.S. Biopharma minority IPO, still under evaluation as of Q2 2026 earnings call
The call

Grifols keeps growing and deleveraging inside a plasma business few can enter, while an unresolved U.S. IPO and lingering Brookfield and Gotham City questions sit over the stock.

Grifols collects blood plasma and turns it into medicines; it is one of the five biggest companies doing this worldwide. The business is genuinely hard to copy because it takes years to get government approval, billions to build the factories, and hundreds of licensed donor centers to collect plasma, which Grifols already owns. The main threat is not a new competitor but rather the company's own debt and the family that owns it: Grifols makes good money and is growing, but a failed takeover offer and an unresolved decision to spin off part of the U.S. business into a new stock listing means the stock price may stay stuck even if the company itself runs fine. If the U.S. spinoff gets approved and priced well, it could clear away this uncertainty and raise the stock; if it gets abandoned, the takeover drama and debt will likely grind on.

Why
01
AI pressure: None apparent. Plasma collection and fractionation are physical, regulated processes; no AI model makes immunoglobulin from software. Could AI do the core job? Unlikely.
02
Bigger players: CSL Behring. CSL is larger ($15.6B vs Grifols' €7.5B) and competes head to head in immunoglobulin and albumin worldwide. Could a giant copy it? No, they are blocked.
03
What protects it. 400+ licensed donor centers, billion-dollar fractionation plants, and multi-year FDA/EMA approvals that can't be copied quickly.
What would change this call
Grifols decides on U.S. Biopharma IPO (announced Mar 2026, pending as of July 2026). Shows whether Grifols can deleverage and reduce takeover/family-control risk.
SPARTA Phase 3 alpha-1 antitrypsin topline results expected Q4 2026. Indicates whether Grifols pipeline expansion beyond plasma succeeds.
Grifols net leverage ratio at next earnings report versus current 4.2x EBITDA. Shows whether debt reduction trend continues or reverses toward 5x.
Key numbers
  • FY2025 revenue €7,524M, up 7% at constant currency (2026-02-26)
  • FY2025 net profit €402M, more than double FY2024 (2026-02-26)
  • Leverage down to 4.2x EBITDA from 4.6x (2026-02-26)
Named risks
  • Elevated leverage at 4.2x EBITDA with 2028 debt maturities still to be resolved. Severity: medium
  • U.S. Biopharma IPO remains undecided as of July 2026, outcome could reshape ownership structure. Severity: medium
  • Active Gotham City defamation litigation (SDNY) and open Spanish criminal probe into short-seller claims. Severity: medium
  • Possible resurfacing of a Brookfield-family take-private bid after 2024 withdrawal. Severity: low
  • Departure of Biopharma president Roland Wandeler disclosed July 2026 creates leadership transition risk. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
CSL BehringcontestingCSL Limited posted ~$15.6B FY2025 revenue vs Grifols' 7.5B euros, remains global leader as of Oct 2025
Takeda (BioLife)contestingRuns competing BioLife plasma-collection network within same oligopoly
OctapharmacontestingNamed among top-5 plasma fractionators holding collective 75-80% global share
Kedrion BiopharmacontestingSmaller peer within same regulated plasma-fractionation oligopoly
Questions people ask
Is Grifols in financial trouble?
Grifols has been cutting leverage, moving net debt to EBITDA from 8.4x down to 4.2x as of 2026-05-07, with a public target to get below 3.5x by end of 2027. Q1 2026 revenue reached 1.7 billion euros and FY2025 free cash flow was 468 million euros, both signs of an improving balance sheet rather than active distress. The company is still classified as protection under test because past governance issues and an unresolved US Biopharma IPO, expected to price by end of 2026, leave uncertainty around the equity story.
Who are Grifols' biggest competitors?
Grifols competes in the small global oligopoly of plasma-derived medicine makers alongside CSL Behring, Takeda, and privately held Octapharma. None of these rivals has documented confirmed share wins against Grifols as of the July 2026 assessment, and CSL Behring's threat during the company's 2024 crisis remains speculative rather than materialized. Plasma collection and fractionation require large regulated infrastructure and long-standing donor networks, which raises the bar for new entrants and helps explain why Grifols' position has held despite its financial troubles.
Is Grifols at risk from AI?
No meaningful AI risk applies here; the assessment lists AI threat as not applicable for Grifols. Plasma collection and fractionation is a physical, regulated manufacturing process that AI models do not touch. The company's challenges are financial and governance related, not technological displacement.
What is Grifols' biggest risk right now?
The biggest open question is not medical market share but the unresolved equity story tied to past governance overhang and the pending US Biopharma minority IPO, expected to price by end of 2026 as announced in March 2026. Grifols also has a leverage target to bring net debt to EBITDA below 3.5x by end of 2027, and its H1 2026 earnings report on July 28, 2026 is a key test of progress on that path. These near-term, dated events carry real weight for how the standing resolves.
Is Grifols losing customers or share to bigger rivals like CSL Behring?
There is no confirmed customer or share loss documented for Grifols as of the July 2026 assessment. CSL Behring has a larger plasma collection network and competing immunoglobulin lines, but its threat during Grifols' 2024 crisis has stayed speculative rather than materialized into lost business. Grifols' own Q1 2026 immunoglobulin sales actually rose 15.3% in constant currency as of 2026-05-07.
What should I watch for with Grifols going into 2027?
Two dated milestones matter most: the H1 2026 earnings report on July 28, 2026, which will show progress toward the leverage target, and the expected pricing of the US Biopharma minority IPO by end of 2026 as announced in March 2026. Beyond that, Grifols has guided to bring net debt to EBITDA below 3.5x by end of 2027, down from the 4.2x level recorded as of 2026-05-07. These are verifiable checkpoints rather than guaranteed outcomes, and readers can track them against the company's own published guidance.
Timeline
  • 2026-07-28H1 2026 results: revenue 3,574M euros (+2.6% cc), net profit 227M euros (+28.7%); IPO still under evaluation
  • 2026-07-28Grifols discloses closure of 29 U.S. donor centers and departure of Biopharma president Roland Wandeler
  • 2026-03-24Board approves evaluating U.S. IPO of minority stake in Biopharma subsidiary
  • 2026-03-17Chronos-PD platform identifies Parkinson's biomarkers up to 12 years before diagnosis using AI and proteomics
  • 2026-02-26FY2025 results: revenue 7,524M euros (+7% cc), net profit 402M euros, leverage falls to 4.2x
  • 2025-04Board states no knowledge of any resumed Brookfield takeover talks
  • 2024-12-10Spanish Audiencia Nacional criminal probe into Gotham City Research over Grifols remains open
  • 2024-12-05SEC drops its own investigation into Gotham City Research
  • 2024-11-27Brookfield withdraws 6.45 billion euro take-private offer for Grifols
  • 2023-08-01Grifols partners with Google Cloud to apply AI to biopharma R&D
Revision history
31 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources